Alphamab Oncology (FRA:3NK)
Germany flag Germany · Delayed Price · Currency is EUR
1.170
+0.040 (3.54%)
At close: Nov 27, 2025

Alphamab Oncology Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
1,1194197421,2181,4371,605
Upgrade
Market Cap Growth
134.60%-43.55%-39.08%-15.24%-10.46%11.71%
Upgrade
Enterprise Value
9532685801,0521,2191,347
Upgrade
Last Close Price
1.120.440.75---
Upgrade
PE Ratio
40.4219.03----
Upgrade
PS Ratio
11.974.9526.5853.8171.10-
Upgrade
PB Ratio
5.071.733.485.765.555.64
Upgrade
P/TBV Ratio
5.071.733.485.765.555.64
Upgrade
P/FCF Ratio
43.2516.61----
Upgrade
P/OCF Ratio
36.6914.91----
Upgrade
EV/Sales Ratio
10.013.1620.7646.4660.34-
Upgrade
EV/EBITDA Ratio
30.3412.24----
Upgrade
EV/EBIT Ratio
41.8520.04----
Upgrade
EV/FCF Ratio
36.8310.62----
Upgrade
Debt / Equity Ratio
0.150.100.150.220.340.10
Upgrade
Debt / EBITDA Ratio
1.051.04----
Upgrade
Debt / FCF Ratio
1.260.98----
Upgrade
Asset Turnover
0.350.290.100.070.06-
Upgrade
Inventory Turnover
0.830.750.770.720.06-
Upgrade
Quick Ratio
4.766.415.553.723.226.52
Upgrade
Current Ratio
4.986.745.843.883.326.67
Upgrade
Return on Equity (ROE)
13.37%9.49%-13.04%-19.00%-19.91%-18.21%
Upgrade
Return on Assets (ROA)
5.22%2.88%-9.50%-11.21%-9.72%-9.32%
Upgrade
Return on Capital (ROIC)
5.76%3.20%-10.55%-12.25%-10.38%-9.89%
Upgrade
Return on Capital Employed (ROCE)
9.40%5.10%-17.30%-25.00%-20.10%-17.70%
Upgrade
Earnings Yield
2.47%5.25%-3.62%-3.63%-3.97%-3.34%
Upgrade
FCF Yield
2.31%6.02%-4.11%-4.79%-4.61%-3.42%
Upgrade
Buyback Yield / Dilution
-3.37%-2.53%-2.50%-0.11%-0.62%-73.29%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.